

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shou, et al

Serial No.: 10/599914

Group Art Unit No.:

Filed: 14 April 2005

Examiner: Unknown

For: "METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY"

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Andrea V. Lockenour
Attorney for Applicants
Registration No. 51,962

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7568
Facsimile (610) 270-5090

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60813 PCT/US	SERIAL NO. 10/599914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Shou, et al.	
		FILING DATE 14 April 2005	GROUP

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AA	2003/072747A1	17 Apr. 2003	Cousens et al.			
AB	2002/102231A1	01 Aug. 2002	Dietsch et al.			
AC	US 6203790B1	20 Mar. 2001	Cousens et al.			
AD	US 5698403	16 Dec. 1997	Cousens et al.			
AE	20050244913A1	03-Nov-2005	Shou, et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	BA WO04089184A1	21 Oct 2004	PCT				
	BB EP1318154A1	11 June 2003	EPO				
	BC WO00/032808	08 June 2000	PCT				
	BD JP 07059597	07 Mar. 1995	Japan				
	BE EP816504A2	07 Jan. 1998	EP				
	BF WO 9509921 A1	13 Apr. 1995	PCT				
	BG JP 06116279A	26 Apr. 1994	Japan				
	BH WO05/001416A2	06 Jan 2005	PCT				
	BI JP 2002-179545	20 June 2002	Japan				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Kosaka, T., et al., "Spectrophotometric Assay for Serum Platelet-Activating Factor Acetylhydrolase Activity," <i>Clinica Chimica Acta</i> (2000) 296(1-2):151-161.
CB	Kosaka, T., et al., "Serum Platelet-Activating Factor Acetylhydrolase (PAFAH) Activity in more than 3000 Healthy Japanese," <i>Clinica Chimica Acta</i> (2001)312(1-2):179-183.
CC	Koenig, W., et al., "Lipoprotein-Associated Phospholipase A ₂ Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men from the General Population" <i>Circulation</i> (Oct. 2004) 110(14):1903-1908.
CD	Balafoutis, O., et al., "Urine of Patients with Nephritic Syndrome Contains the Plasma Type of PAF-Acetylhydrolase Associated with Lipoproteins," <i>Nephron Physiology</i> (2004)97(3):45-52.
CE	Sarchielli, P., et al., "Platelet-Activating Factor (PAF) in Internal Jugular Venous Blood of Migraine without Aura Patients Assessed During Migraine Attacks," <i>Cephalgia</i> (2004) 24(8):623-630.
CF	Karkabounas, A., et al., "Quantitative Fluorescence Determination of Phospholipase A ₂ and PAF Acetylhydrolase in Biological Fluids using High Performance Liquid Chromatography," <i>Chemistry and Physics of Lipids</i> (June 2004)130(1):69-70.
CG	Brites, F., et al., "Paraoxonase 1 and Platelet-Activating Factor Acetylhydrolase Activities in Patients with Low HDL-Cholesterol Levels with or without Primary Hypertriglyceridemia," <i>Archives of Medical Research</i> (May 2004)35(3):235-240.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 606; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. PU60813 PCT/US	SERIAL NO. 10/599914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Shou, et al.	
		FILING DATE 14 April 2005	GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CH	Kujiraoka, T., et al., "Altered Distribution of Plasma PAF-AH between HDLs and other Lipoproteins in Hyperlipidemia and Diabetes Mellitus," <i>Journal of Lipid Research</i> (October 2003) 44:2006-14.
CI	Ito, T., et al., "Scrum PAF-Acetylhydrolase (PAF-AH) in Hepatobiliary Disease," <i>Japanese Pharmacology and Therapeutics</i> (2002) 30/Suppl. 2.
CJ	Unno, N., et al., "Single Nucleotide Polymorphism (G ⁹⁹⁴ →T) in the Plasma Platelet-Activating Factor-Acetylhydrolase Gene is Associated with Graft Patency of Femoropopliteal Bypass," <i>Surgery</i> (2002) 132(1):66-71.
CK	Dada, N., et al., "Lp-PLA2: An Emerging Biomarker of Coronary Heart Disease," <i>Expert Review of Molecular Diagnostics</i> (Jan. 2002) 2(1):17-22.
CL	Ibe, B., et al., "Platelet Activating Factor Acetylhydrolase Activity in Lamb Lungs is Up-Regulated in the Immediate Newborn Period," <i>Molecular Genetics and Metabolism</i> (Jan. 2000) 69(1):46-55.
CM	Deigner, H., et al., "Novel reversible, irreversible and fluorescent inhibitors of platelet-activating factor acetylhydrolase as mechanistic probes," <i>Atherosclerosis</i> (May 1999) 144(1):79-90.
CN	Kitsioulis, E., et al., "Differential Determination of Phospholipase A ₂ and PAF-Acetylhydrolase in Biological Fluids Using Fluorescent Substrates," <i>Journal of Lipid Research</i> (Dec. 1999) 40(12):2346-2356.
CO	Hendrickson, H.S., et al., "Intramolecularly Quenched BODIPY-Labeled Phospholipids Analogs in Phospholipase A ₂ and Platelet-Activating Factor Acetylhydrolase assays and <i>in vivo</i> Fluorescence Imaging," <i>Analytical Biochemistry</i> (Dec. 1999) 276(1):27-35.
CP	Akiyama, M., et al., "Identification of a Major PAF Acetylhydrolase in Human Serum/Plasma as a 43 kDa Glycoprotein Containing about 9 kDa Asparagine-Conjugated Sugar Chain(s)," <i>Journal of Biochemistry</i> (May 1998) 123(5):786-789.
CQ	Servillo, L., et al., "Simultaneous Determination of Lysophospholipids by High-performance Liquid Chromatography with Fluorescence Detection," <i>Journal of Chromatography</i> (1997) 689(2):281-286.
CR	Patrick, D.A., et al., "Reduced PAF-Acetylhydrolase Activity is Associated with Postinjury Multiple Organ Failure," <i>Shock</i> (Mar. 1997) 7(3):170-174.
CS	Tsukioka, K., et al., "Increased Plasma Level of Platelet-Activating Factor (PAF) and Decreased Serum PAF Acetylhydrolase (PAFAH) Activity in Adults with Bronchial Asthma," <i>Journal of Investigational Allergology and Clinical Immunology</i> (1996) 6(1):22-29.
CT	Balestrieri, C., et al., "Measurement of Platelet-Activating Factor Acetylhydrolase Activity by Quantitative High-Performance Liquid Chromatography Determination of Coumarin-Derivatized 1-0-alkyl-2-sn-lysoglycerol-3-phosphorylcholine," <i>Analytical Biochemistry</i> (Jan. 1996) 233(2):145-50.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60813 PCT/US	SERIAL NO. 10/599914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Shou, et al.	
		FILING DATE 14 April 2005	GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CU	Riehl, T. E. and Stenson W.F., "Platelet-activating factor acetylhydrolases in Caco-2 cells and epithelium of normal and ulcerative colitis patients," <i>Gastroenterology</i> (1995)109(6):1826-1834.
CV	Masaki, A., et al., "New Serum PAF acetylhydrolase detection method used with the Blotting Method and Beta of H ³ acetyl-PAF," <i>Proceedings of Japanese Conference on the Biochemistry of Lipids</i> (1994)36:43-46.
CW	Hemmings, R., et al., "Platelet-Activating Factor Acetylhydrolase Activity in Peritoneal Fluids of Women with Endometriosis," <i>Obstetrics and Gynecology</i> (Feb. 1993)81(2):276-279.
CX	Miwa, M., et al., "On Development of a Measurement Method of Serum PAF Acetylhydrolase Activity Using an Automatic Analyser, and the Clinical Significance of Serum PAF Acetylhydrolase Defect," <i>Proceedings of Japanese Conference on the Biochemistry of Lipids</i> (1992)34:305-308.
CY	Stafforini, D., et al., "Platelet-Activating Factor Acetylhydrolase in Human erythrocytes," <i>Methods in Enzymology</i> (1991)197:411-425
CZ	Kirschbaum, B., "Platelet Activating Factor Acetylhydrolase activity in the urine of patients with renal disease," <i>Clinical Chimica Acta</i> (June 14 1991)199(2):139-146.
CAA	Imazumi, T., et al., "Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from healthy habitual cigarette smokers" <i>Heart and Vessels</i> (1990)5(2):81-86.
CAB	Masaharu, M., "Measurement Methods of Platelet Activating Factor (PAF) and PAF Acetylhydrolase (PAFAH) Activity," <i>SRL Hokan</i> (1989)13(3): 36-41.
CAC	Schindler, P. W., et al., "Fluorophore-labeled ether lipids: substrates for enzymes of the platelet-activating factor cycle in peritoneal polymorphonuclear leukocytes," <i>Analytical Biochemistry</i> (Nov 1988) 174(2):477-84.
CAD	Miyake, M. M., et al., "Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children." <i>Journal of Clinical Investigation</i> (Dec. 1988)82(6):1983-1991.
CAE	Miwa, M., et al., "Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children," <i>Japanese Journal of Inflammation</i> (1988)8(4):327-333.
CAF	Satoh, K., et al., "Platelet-activating factor (PAF) acetylhydrolase and plasma lipoproteins: Relative distribution of the activity among lipoprotein classes," <i>Journal of Japan Atherosclerosis Society</i> (1988)16(4):501-504.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 606; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60813 PCT/US	SERIAL NO. 10/599914
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Shou, et al.	
		FILING DATE 14 April 2005	GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CAG	Stafforini, D., et al., "Human Plasma Platelet-Activating Factor Acetylhydrolase. Purification and Properties," <i>Journal of Biological Chemistry</i> (1987)262(9):4223-4230.
CAH	Kawamura, Y., "A Simple Measurement of Plasma Platelet-Activating Factor (PAF) Acetylhydrolase, Normal Level Activity, and Distribution Among Lipoprotein Fractions," <i>Japanese Journal of Clinical Pathology</i> (Oct. 1987)35(10):1149-1153.
CAI	Pritchard, P. H., et al., "The Degradation of Platelet-Activating Factor in the Plasma of a Patient with Familial High Density Lipoprotein Deficiency (Tangier Disease)" <i>Blood</i> (1985) 66(6):1476-1478.
CAJ	Caslake, M. J., et al., "Lipoprotein-associated Phospholipase A ₂ platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease," <i>Atherosclerosis</i> 150(2): 413-9, (June 2000)
CAK	Flegar-Mestric, Z., et al., "Serum platelet-activating factor acetylhydrolase activity in patients with angiographically established cerebrovascular stenosis," <i>Clinical Chemistry and Laboratory Medicine, Processing of the IFCC-FESCC European Congress 15th Barcelona, Spain:</i> 369-372 (June 1-5, 2003) (Publisher Monduzzi Editore, Bologna, Italy)
CAL	Masaki, A., et al., "Determination of Platelet-Activating Factor Acetylhydrolase Activity by Blotting, B-Radioluminescence, and Ultrahigh-Sensitivity Television Camera Detection," <i>Analytical Biochemistry</i> 21(2):295-299 (May 1994).
CAM	Karlan Research Products Corporation, Santa Rosa, CA, "Auto PAF-AH Serum (plasma) platelet-activating factor (PAF) acetylhydrolase assay - Instruction Manual" (2005)
CAN	Cayman Chemical, Ann Arbor, MI "PAF Acetylhydrolase Assay Kit" Catalog No. 760901.
CAO	DiaDexus Inc., "Enzyme Immunoassay for the Quantitative Determination of Lp-PLA ₂ in Human Plasma and Serum" (August 2005).
CAP	Thirkettle, J., et al., "SB-253514 and Analogues: Novel Inhibitors of Lipoprotein-Associated Phospholipase A ₂ Produced by <i>Pseudomonas fluorescens</i> DSM 11579 I. Fermentation of Producing Strain, isolation and Biological Activity," <i>J. Antibiotics</i> (July 2000)53 (7):664-669
CAQ	Thirkettle, J., et al., "SB-253514 and Analogues: Novel Inhibitors of Lipoprotein-Associated Phospholipase A ₂ Produced by <i>Pseudomonas fluorescens</i> DSM 11579 III Biotransformation Using Naringinase," <i>J. Antibiotics</i> (July 2000)53 (7):733-735
CAR	Boyd, H. F., et al., "N-1 Substituted Pyrimidin-4-ones: Novel, Orally Active Inhibitors of Lipoprotein-Associated Phospholipase A ₂ ," <i>Bioorg Med Chem Lett</i> 10 (Dec 2000) 2557-2561
CAS	Boyd, H. F., et al., "2-(Alkylthio)pyrimidin-4-ones as Novel, Reversible Inhibitors of Lipoprotein-Associated Phospholipase A ₂ ," <i>Bioorg Med Chem Lett</i> 10 (Feb 2000) 395-398
CAT	Tew, D. G., et al., "Mechanism of Inhibition of LDL Phospholipase A ₂ by Monocyclic-B-lactams. Burst Kinetics and the Effect of Stereochemistry," <i>Biochem</i> (June 1998) 37:10087-10093
CAU	Tew, D. G., et al., "Purification, Properties, Sequencing, and Cloning of a Lipoprotein-Associated, Serine-Dependent Phospholipase Involved in the Oxidative Modification of Low-Density Lipoproteins," <i>Arteriosclerosis, Thrombosis Vasc Biol</i> (April 1996) 16(4):591-599.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.